glp-1/glp1 Glucagon-like peptide 1 (GLP-1) Not available to the following states GLP-1 Safety Check - National

coagulans and GBRS improved the overall inflammatory status of the experimental IBD model through synergistic functioning

For patients with type 2 diabetes, other medication classes with fewer gastrointestinal effects might be preferable, such as SGLT-2 inhibitors or DPP-4 inhibitors

Treatment should improve your overall health, not diminish your enjoyment of life

Summary of CV and Renal Outcomes with SGLT2i and DPP4i Agents SGLT2: Inhibitor Cardiovascular Outcome Trials Cardiovascular outcome trials (CVOTs) have consistently shown that treatment with SGLT2i reduces hospitalization for heart failure (HHF) and secondary renal outcomes in terms of incident or worsening nephropathy in patients with T2DM and CV disease

10.1016/s2213-8587(18)30268-7 57 NielsenM